The international life sciences journal Genetic Engineering News (GEN) has placed Sana Alajmovic, CEO of Sigrid Therapeutics, on its Top 10 Under 40 of 2019, a list of rising stars making their mark in business and academia.
The list casts its net internationally to identify emerging leaders among life sciences professionals working in a university, a company, a non-profit, or a government agency.
As CEO of a young life sciences company specialising in the field of diabetes, Sana is one of five honourees holding positions in a business, along with four in academia, and one who has positions at both an academic institution and a not-for-profit healthcare system.
“I am incredibly honoured to be recognized as an emerging leader within the field of life sciences. I was 26 years old when I founded Sigrid together with Professor Tore Bengtsson, with a vision to prevent disease and improve human health. I am proud of our team’s focused and dedicated work in developing our scientific discovery from laboratory to market. Our lead product candidate SiPore15 for the prevention of type 2 diabetes is currently being evaluated in a second clinical trial called STAR in Finland and Sweden. We look forward to sharing the results of this study with the scientific and investor community in the third quarter of 2019,” says Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics.
Photo of Sana Alajmovic: Sigrid Therapeutics